KR102810837B1 - 혈장 칼리크레인 억제제의 결정성 염 - Google Patents

혈장 칼리크레인 억제제의 결정성 염 Download PDF

Info

Publication number
KR102810837B1
KR102810837B1 KR1020217013734A KR20217013734A KR102810837B1 KR 102810837 B1 KR102810837 B1 KR 102810837B1 KR 1020217013734 A KR1020217013734 A KR 1020217013734A KR 20217013734 A KR20217013734 A KR 20217013734A KR 102810837 B1 KR102810837 B1 KR 102810837B1
Authority
KR
South Korea
Prior art keywords
crystalline salt
delete delete
salt
compound
crystalline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020217013734A
Other languages
English (en)
Korean (ko)
Other versions
KR20210087037A (ko
Inventor
야야 엘-카탄
야라가다 에스. 바부
Original Assignee
바이오크리스트파마슈티컬즈,인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=70457981&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR102810837(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 바이오크리스트파마슈티컬즈,인코포레이티드 filed Critical 바이오크리스트파마슈티컬즈,인코포레이티드
Publication of KR20210087037A publication Critical patent/KR20210087037A/ko
Application granted granted Critical
Publication of KR102810837B1 publication Critical patent/KR102810837B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/44—Oxygen and nitrogen or sulfur and nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0029—Parenteral nutrition; Parenteral nutrition compositions as drug carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Physiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Mycology (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
KR1020217013734A 2018-11-02 2019-11-01 혈장 칼리크레인 억제제의 결정성 염 Active KR102810837B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862754983P 2018-11-02 2018-11-02
US62/754,983 2018-11-02
PCT/US2019/059385 WO2020092898A1 (en) 2018-11-02 2019-11-01 Crystalline salts of a plasma kallikrein inhibitor

Publications (2)

Publication Number Publication Date
KR20210087037A KR20210087037A (ko) 2021-07-09
KR102810837B1 true KR102810837B1 (ko) 2025-05-20

Family

ID=70457981

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217013734A Active KR102810837B1 (ko) 2018-11-02 2019-11-01 혈장 칼리크레인 억제제의 결정성 염

Country Status (22)

Country Link
US (11) US10662160B1 (cg-RX-API-DMAC7.html)
EP (1) EP3873463A4 (cg-RX-API-DMAC7.html)
JP (2) JP2022505670A (cg-RX-API-DMAC7.html)
KR (1) KR102810837B1 (cg-RX-API-DMAC7.html)
CN (1) CN112969458A (cg-RX-API-DMAC7.html)
AR (1) AR116951A1 (cg-RX-API-DMAC7.html)
AU (1) AU2019374115B8 (cg-RX-API-DMAC7.html)
BR (1) BR112021008249A2 (cg-RX-API-DMAC7.html)
CA (1) CA3117123A1 (cg-RX-API-DMAC7.html)
CL (1) CL2021001094A1 (cg-RX-API-DMAC7.html)
CO (1) CO2021007172A2 (cg-RX-API-DMAC7.html)
EA (1) EA202191192A1 (cg-RX-API-DMAC7.html)
IL (2) IL322896A (cg-RX-API-DMAC7.html)
MA (1) MA54087A (cg-RX-API-DMAC7.html)
MX (1) MX2021004917A (cg-RX-API-DMAC7.html)
PE (1) PE20211280A1 (cg-RX-API-DMAC7.html)
PH (1) PH12021550883A1 (cg-RX-API-DMAC7.html)
PY (1) PY1991831A (cg-RX-API-DMAC7.html)
SG (1) SG11202103804TA (cg-RX-API-DMAC7.html)
TW (1) TW202031255A (cg-RX-API-DMAC7.html)
UY (1) UY38438A (cg-RX-API-DMAC7.html)
WO (1) WO2020092898A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20221373T1 (hr) 2014-03-07 2023-01-06 Biocryst Pharmaceuticals, Inc. Supstituirani pirazoli kao inhibitori kalikreina u ljudskoj plazmi
UY38438A (es) 2018-11-02 2020-05-29 Biocryst Pharm Inc Sales cristalinas de un inhibidor de calicreína plasmática
WO2021025969A1 (en) * 2019-08-02 2021-02-11 Teva Pharmaceuticals International Gmbh Solid state forms of berotralstat
CN116375648A (zh) * 2023-03-22 2023-07-04 苏州农平科技发展有限公司 贝罗司他中间体的制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130211086A1 (en) 2010-05-19 2013-08-15 Sandoz Ag Purification of posaconazole and of posaconazole intermediates
WO2015134998A1 (en) * 2014-03-07 2015-09-11 Biocryst Pharmaceuticals, Inc. Human plasma kallikrein inhibitors

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4559157A (en) * 1983-04-21 1985-12-17 Creative Products Resource Associates, Ltd. Cosmetic applicator useful for skin moisturizing
EP1828187A2 (en) 2004-12-15 2007-09-05 Brystol-Myers Squibb Company Crystalline forms of a factor xa inhibitor
CN101495468A (zh) * 2006-07-31 2009-07-29 艾克提弗赛特制药股份有限公司 血浆激肽释放酶抑制剂
EP2051707B1 (en) 2006-07-31 2013-07-17 Activesite Pharmaceuticals, Inc. Inhibitors of plasma kallikrein
JP5808818B2 (ja) 2010-11-25 2015-11-10 ラツィオファーム・ゲーエムベーハー アファチニブの新規塩及び多形形態
GB201212081D0 (en) * 2012-07-06 2012-08-22 Kalvista Pharmaceuticals Ltd New polymorph
FI4019022T3 (fi) 2015-10-01 2024-04-19 Biocryst Pharm Inc Ihmisen plasman kallikreiinin estäjiä
UY38438A (es) 2018-11-02 2020-05-29 Biocryst Pharm Inc Sales cristalinas de un inhibidor de calicreína plasmática
EP4010320A4 (en) 2019-08-06 2023-08-16 Biocryst Pharmaceuticals, Inc. Process-scale synthesis of a plasma kallikrein inhibitor

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130211086A1 (en) 2010-05-19 2013-08-15 Sandoz Ag Purification of posaconazole and of posaconazole intermediates
WO2015134998A1 (en) * 2014-03-07 2015-09-11 Biocryst Pharmaceuticals, Inc. Human plasma kallikrein inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Topics in Current Chemistry (1998) Vol. 198, pp. 163-208

Also Published As

Publication number Publication date
US12552750B2 (en) 2026-02-17
US11618733B2 (en) 2023-04-04
BR112021008249A2 (pt) 2021-08-03
MX2021004917A (es) 2021-06-18
TW202031255A (zh) 2020-09-01
US12545647B2 (en) 2026-02-10
IL282454A (en) 2021-06-30
US20220204454A1 (en) 2022-06-30
AU2019374115A1 (en) 2021-06-03
US20250388549A1 (en) 2025-12-25
CL2021001094A1 (es) 2021-10-15
JP2024109860A (ja) 2024-08-14
AU2019374115B1 (en) 2025-07-17
US20250388545A1 (en) 2025-12-25
US12545646B2 (en) 2026-02-10
US20240109844A1 (en) 2024-04-04
US10662160B1 (en) 2020-05-26
UY38438A (es) 2020-05-29
CO2021007172A2 (es) 2021-06-10
US20250388547A1 (en) 2025-12-25
US20250376447A1 (en) 2025-12-11
EP3873463A4 (en) 2022-06-22
KR20210087037A (ko) 2021-07-09
IL322896A (en) 2025-10-01
SG11202103804TA (en) 2021-05-28
US20250376448A1 (en) 2025-12-11
EA202191192A1 (ru) 2021-09-23
US11117867B2 (en) 2021-09-14
EP3873463A1 (en) 2021-09-08
US12590068B2 (en) 2026-03-31
US20200140389A1 (en) 2020-05-07
WO2020092898A1 (en) 2020-05-07
MA54087A (fr) 2022-02-09
PE20211280A1 (es) 2021-07-19
US12344585B2 (en) 2025-07-01
US20250388546A1 (en) 2025-12-25
CA3117123A1 (en) 2020-05-07
US20250388548A1 (en) 2025-12-25
PY1991831A (es) 2020-07-03
JP2022505670A (ja) 2022-01-14
US20200308118A1 (en) 2020-10-01
CN112969458A (zh) 2021-06-15
AR116951A1 (es) 2021-06-30
US12590069B2 (en) 2026-03-31
US12545645B2 (en) 2026-02-10
PH12021550883A1 (en) 2022-02-21
AU2019374115B8 (en) 2025-08-07

Similar Documents

Publication Publication Date Title
US12545647B2 (en) Crystalline salts of a plasma kallikrein inhibitor
KR102928815B1 (ko) 혈장 칼리크레인 억제제의 공정-스케일 합성
CA2999164A1 (en) Human plasma kallikrein inhibitors
HK40052614A (en) Crystalline salts of a plasma kallikrein inhibitor
OA20652A (en) Process-scale synthesis of a plasma kallikrein inhibitor.

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20210506

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20221020

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20241127

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20250304

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20250516

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20250516

End annual number: 3

Start annual number: 1

PG1601 Publication of registration